title: Immune responses following stereotactic body radiotherapy for stage I primary lung cancer.
abstract: OBJECTIVE
  Immune responses following stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) were examined from the point of view of lymphocyte subset counts and natural killer cell activity (NKA).
  
  
  METHODS
  Peripheral blood samples were collected from 62 patients at 4 time points between pretreatment and 4 weeks post-treatment for analysis of the change of total lymphocyte counts (TLC) and lymphocyte subset counts of CD3⁺, CD4⁺, CD8⁺, CD19⁺, CD56⁺, and NKA. In addition, the changes of lymphocyte subset counts were compared between patients with or without relapse. Further, the correlations between SBRT-related parameters and immune response were analyzed for the purpose of revealing the mechanisms of the immune response.
  
  
  RESULTS
  All lymphocyte subset counts and NKA at post-treatment and 1 week post-treatment were significantly lower than pre-treatment (P < 0.01). No significant differences in the changes of lymphocyte subset counts were observed among patients with or without relapse. The volume of the vertebral body receiving radiation doses of 3 Gy or more (VV₃) significantly correlated with the changes of nearly all lymphocyte subset counts.
  
  
  CONCLUSIONS
  SBRT for stage I NSCLC induced significant immune suppression, and the decrease of lymphocyte subset counts may be associated with exposure of the vertebral bone marrow.
authors: Department of Radiation Oncology, Kofu Municipal Hospital, 366 Masutsubo, Kofu, Yamanashi 4000832, Japan.
authors: Yoshiyasu
authors: Y
authors: Maehata
authors: Hiroshi
authors: H
authors: Onishi
authors: Kengo
authors: K
authors: Kuriyama
authors: Shinichi
authors: S
authors: Aoki
authors: Masayuki
authors: M
authors: Araya
authors: Ryo
authors: R
authors: Saito
authors: Licht
authors: L
authors: Tominaga
authors: Mitsuhiko
authors: M
authors: Oguri
authors: Tsutomu
authors: T
authors: Araki
mesh_terms: D019070:Cell Lineage; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007113:Immunity, Innate; D007694:Killer Cells, Natural / Q000276:immunology* / Q000378:metabolism; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*; D016131:Lymphocyte Subsets / Q000145:classification / Q000276:immunology* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy; D009367:Neoplasm Staging; D016634:Radiosurgery / Q000009:adverse effects*